Small start­up touts a PhI­II suc­cess in rare 'but­ter­fly skin' dis­ease af­ter an FDA hold rout­ed shares

More than three years af­ter get­ting held up by the FDA, Abeona Ther­a­peu­tics is trum­pet­ing a da­ta drop for the rare “but­ter­fly skin” dis­ease.

The biotech tout­ed Phase III re­sults from the EB-101 pro­gram Thurs­day morn­ing, say­ing the drug achieved both pri­ma­ry goals. EB-101 healed wounds by at least 50% at a sig­nif­i­cant­ly greater mar­gin than a place­bo over six months, and sig­nif­i­cant­ly re­duced pa­tients’ pain as­so­ci­at­ed with the wounds.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER